Good morning, everyone, and how are you today? This will be an abbreviated session, since the Thanksgiving holiday is approaching on this side of the pond. Nonetheless, we are keeping busy. For starters, we are downing that mandatory cup of stimulation – and will certainly reach for still more as the day wears on so that we may tidy up the Pharmalot corporate campus and prepare to meet some VIPs. Meanwhile, here are some tidbits. Catch you soon…
Aetna Will Cover Arena And Vivus Diet Pills (TheStreet)
Bristol And Pfizer Bloodthinner Wins EU Approval (Associated Press)
BASF To Buy Fish Oil Maker Pronova For $845M (Reuters)
Teva Is Focused On Smaller M&A, Chairman Says (Bloomberg News)
FDA OKs Novartis Cell Culture Flu Vaccine (Pharma Times)
Cipla To Buy Cipla Medpro for $215M (Economic Times)
Xoma Drug Combo Lowers High Blood Pressure In Study (Reuters)
Nestle Purchase Of Pfizer Unit Blocked In Mexico (Bloomberg News)
India Imposes One Price Cap On Insulins (Business Standard)
India Is Urged To Adopt Market-Based Pricing (Pharma Times)
vacuum pic thx to wordridden on flickr
2 Comments
http://si.wsj.net/public/resources/images/ED-AQ098_PNS112_NS_20121120172302.jpg
NDA 021861 Patanase (olopatadine hydrochloride) Nasal Spray
http://www.pharmalive.com/News/index.cfm?articleid=867858&categoryid=10
Two steps forward after one step back?
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM328640.pdf